Biden Drug Price Negotiation Policy Survives Key Legal Fight (2)

March 1, 2024, 5:52 PM UTCUpdated: March 1, 2024, 9:50 PM UTC

The Biden administration secured another major win Friday in its battle to defend a government drug price-setting program after a federal judge struck down administrative and constitutional claims brought by AstraZeneca.

Chief Judge Colm F. Connolly for the US District Court for the District of Delaware ruled AstraZeneca PLC doesn’t have Article III standing to challenge the lawfulness of the government’s scheme and “has not identified a property interest protected by the Constitution that is put in jeopardy by the Program.”

AstraZeneca in August 2023 challenged the Medicare Drug Price Negotiation Program authorized by the 2022 Inflation Reduction Act, which ...

Learn more about Bloomberg Law or Log In to keep reading:

Learn About Bloomberg Law

AI-powered legal analytics, workflow tools and premium legal & business news.

Already a subscriber?

Log in to keep reading or access research tools.